+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
C

Actively Recruiting

Researchers are evaluating sacituzumab tirumotecan alone and in combination with pembrolizumab compared to the Treatment of Physicians Choice TPC in participants with hormone receptor positivehuman epidermal growth factor receptor-2 negative HRHER2- unresectable locally advanced or metastatic breast cancer. The study aims to determine if these treatments improve progression-free survival PFS based on standardized tumor response criteria, with a focus on participants who have progressed after endocrine therapy and are chemotherapy candidates. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given every two weeks by intravenous infusion until disease progression or stopping, sacituzumab tirumotecan plus pembrolizumab the latter given every six weeks by intravenous infusion for up to approximately two years, or a physicians choice of chemotherapy including options such as paclitaxel, nab-paclitaxel, capecitabine, or liposomal doxorubicin with varying dosing schedules. Treatments continue until disease progression or discontinuation. Throughout the study, participants undergo regular assessments including tumor imaging reviewed by a blinded independent central review to evaluate progression-free survival up to about 40 months. Additional measures include overall survival, response rates, quality of life questionnaires, and safety monitoring for adverse events over extended follow-up periods up to about 95 months. The study involves scheduled visits for treatment administration and monitoring, with data collected on health status, physical and emotional functioning, and treatment tolerability.

Age: 18Years +All GendersPhase 3
259 locations
P

Actively Recruiting

Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
329 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
A

Actively Recruiting

Researchers are investigating whether patients with locally advanced cervical cancer who still have detectable cell-free human papillomavirus DNA cfHPV-DNA in their plasma after standard treatment may benefit from additional chemotherapy. This trial is a prospective, randomized, multicenter clinical study designed to evaluate adjuvant chemotherapy based on this biomarker. The study focuses on patients who have undergone chemoradiotherapy and have persistent cfHPV-DNA, as this may indicate ongoing disease activity. Participants first receive standard treatment with concomitant chemoradiotherapy, including doses of radiation and weekly cisplatin. Four weeks after completing this treatment, a blood test is conducted to detect cfHPV-DNA in plasma. Patients with positive cfHPV-DNA results are randomly assigned to either receive two additional cycles of adjuvant chemotherapy with cisplatin and gemcitabine or to be monitored without further chemotherapy. Patients in both groups undergo regular follow-up every four months, including plasma cfHPV-DNA testing, CT scans of the chest, MRI scans of the abdomen and pelvis, and clinical and gynecological exams. During the study, participants are closely monitored for progression-free survival, overall survival, treatment response, quality of life, and any toxic effects of treatment. Follow-up assessments occur at regular intervals from 7 to 120 days after treatment. The total duration of participant involvement varies based on follow-up schedules. The study uses a single-blind design and randomized allocation to ensure scientific rigor while maintaining patient safety throughout the trial period.

Age: 18Years - 70YearsFEMALEPhase 3
26 locations
S

Actively Recruiting

Researchers are evaluating the use of adjuvant calderasib combined with subcutaneous pembrolizumab and berahyaluronidase alfa MK-3475A compared to adjuvant placebo plus MK-3475A in participants with completely resected stage IIA-IIIB N2, KRAS G12C-mutant non-small cell lung cancer. This phase 3, randomized, double-blind study focuses on participants who have previously received either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The main goal is to compare disease-free survival between the treatment groups. Participants are assigned to one of two groups one group receives daily calderasib and MK-3475A every six weeks for up to nine doses, while the other group receives a daily placebo plus MK-3475A on the same schedule. The study treatments are administered as oral tablets for calderasib or placebo, and subcutaneous injections for MK-3475A. Treatment continues for up to nine doses or until disease progression or other criteria are met. During the study, participants will undergo regular assessments including imaging scans such as contrast-enhanced chest or abdomen CT or MRI to confirm no evidence of disease before starting treatment. Researchers will monitor disease-free survival up to approximately 11 years, along with overall survival, lung cancer specific survival, distant metastasis-free survival, quality of life measures, and safety outcomes. Adverse events and treatment discontinuations will be tracked for up to 13.5 years, ensuring long-term safety and efficacy monitoring.

Age: 18Years +All GendersPhase 3
120 locations
G

Actively Recruiting

Researchers are evaluating the efficacy and safety of Datopotamab Deruxtecan Dato-DXd combined with Rilvegostomig, or Rilvegostomig alone, compared with Pembrolizumab alone as first-line treatments for people with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC. Participants must have high PD-L1 expression tumor cells 50% and no actionable genomic mutations. This is a Phase III, randomized, open-label global study focusing on these treatments for this specific lung cancer type. Participants will be assigned to one of three groups one receiving Dato-DXd plus Rilvegostomig, another receiving Rilvegostomig alone, and a third receiving Pembrolizumab alone. All treatments are given by intravenous infusion every three weeks on Day 1 of each 21-day cycle. The study will monitor participants over several years to compare these therapies as first-line options. During the study, participants will undergo regular assessments including imaging and tumor sampling to measure progression-free survival and overall survival, focusing on those with TROP2 biomarker positivity. Other evaluations include response rates, duration of response, lung cancer symptoms, quality of life, physical functioning, pharmacokinetics, and immunogenicity over approximately 4 to 6 years. Safety monitoring and long-term follow-up are part of the participant involvement.

Age: 18Years +All GendersPhase 3
290 locations

1-10 of 12

1